Tamsulosin OCAS

Phase 3Small molecule

Astellas

Tamsulosin OCAS is one of 115 small molecule programs targeting Dysuria. It is currently in Phase 3.

Indications

Total Trials

Active Trials

114

Competitors

Pipeline

Status by Indication[3][1]

Indication

DysuriaActive, not recruiting

Neurogenic BladderActive, not recruiting

Chronic ProstatitisActive, not recruiting

Benign Prostatic HyperplasiaActive, not recruiting

Urinary RetentionActive, not recruiting

Lower Urinary Tract SymptomActive, not recruiting

HypertensionActive, not recruiting

DysuriaPreclinical

Active, not recruiting

Neurogenic BladderPhase 2/Phase 3

Active, not recruiting

Chronic ProstatitisPhase 2

Active, not recruiting

Benign Prostatic HyperplasiaPhase 2/Phase 3

Active, not recruiting

Urinary RetentionPhase 3

Active, not recruiting

Lower Urinary Tract SymptomPhase 2

Active, not recruiting

HypertensionPhase 1

Active, not recruiting

Competition

Competitive Landscape

566 competitors in Hypertension

#DrugCompanyPhaseTrials

Tamsulosin OCAS

Astellas

Phase 3

1 2

Edarbi

Takeda

Preclinical

10 3

Benicar

Novartis

Preclinical

7 4

Apresoline

Novartis

Preclinical

7 5

Zebeta

Teva

Preclinical

6 6

Edarbi

Takeda

Preclinical

4 7

Aceon

Institut de Recherches Internationales Servier

Preclinical

5 8

Winrevair

Alphagan

Deltavit

HHyundai Pharmaceutical Co., LTD.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Ureteral Stent-Related Symptom

NCT06803030

Post-ApprovalRecruiting

Prostate

NCT07357324

Clinical

Trials by Indication[1]

Benign Prostatic Hyperplasia5 trials

Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia

Completed· Astellas logo

Astellas·Phase 4·NCT00771394·638 enrolled

Composite Steep-pulseTreatment Device Used in Patients With Benign Prostatic Hyperplasia

Completed·RREMD Medical Technology·Phase 2/3·NCT05531344·160 enrolled

The Safety and Effectiveness of Steep Pulse Therapy System for the Ablation of Benign Prostatic Hyperplasia

Recruiting·FFirst Affiliated Hospital of Zhejiang University·N/A·NCT06867315·10 enrolled

Show 2 more trials

Study to Evaluate the Symptomatic Relief Effects of FLOMAX® in Patients With Signs and Symptoms of Benign Prostatic Hyperplasia

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 4·NCT02244242·493 enrolled

A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)

Completed· Astellas logo

Astellas·Phase 4·NCT02757768·715 enrolled

Urinary retention5 trials

Post-Operative Urinary Retention (POUR) in Thoracic Surgery Patients Receiving Prophylactic Tamsulosin

Terminated·UUniversity of Massachusetts, Worcester·Phase 4·NCT04994431·109 enrolled

Prophylactic Tamsulosin in Prevention of Post-operative Urinary Retention in Men After Transanal Endoscopic Microsurgery

Unknown status·—·Phase 2·NCT03314025·158 enrolled

Use of Tamsulosin to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery

Terminated·MMayo Clinic·Phase 3·NCT01568918·90 enrolled

Show 2 more trials

Prevention of Post Operative Urinary Retention After Thoracic Surgery Trial

Recruiting·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 2·NCT06262048·60 enrolled

REduction of Post-Operative Urinary Retention With Tamsulosin Versus Placebo (REPOURT- P) Trial

Unknown status·MMcMaster University·Phase 3·NCT04159077·350 enrolled

Neurogenic bladder2 trials

Study to Evaluate the Efficacy and Safety of Tamsulosin in Children With Neurogenic Bladder

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2/3·NCT00796614·231 enrolled

PK/PD, Long-term Safety and Efficacy of Tamsulosin Treatment in Children With Neurogenic Bladder

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT00340704·143 enrolled

Lower Urinary Tract Symptom2 trials

Study of FLOMAX® Versus Placebo in Female Patients With Lower Urinary Tract Symptoms (LUTS) With a Significant Component of Voiding Symptoms

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT02244281·74 enrolled

Solifenacin Succinate With Tamsulosin HCl in Males With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction

Completed· Astellas logo

Astellas·Phase 2·NCT00507455·222 enrolled

Treatment2 trials

A Study With Combination Treatment (Tamsulosin Hydrochloride and Solifenacin Succinate) in Male Patients With LUTS/BPH

Completed· Astellas logo

Astellas·Phase 2·NCT00510406·919 enrolled

A Study to Evaluate the Tolerability and Efficacy of Tamsulosin 0.4mg OCAS Formulation in Patients Who Are Unsatisfied With the Treatment of Tamsulosin 0.2mg Conventional Formulation

Completed· Astellas logo

Astellas·Phase 4·NCT02180789·100 enrolled

10 more indications

Chronic Prostatitis2 trials

Chronic Prostatitis Collaborative Research Network Clinical Trial- Ciprofloxacin and Tamsulosin

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT04552431·196 enrolled

Efficacy and Safety of Ningmitai Capsule in Patients With Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Completed·XXintian Pharmaceutical·Phase 4·NCT05890235·323 enrolled

Ureteral Stent-Related Symptom1 trial

Study of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms

Recruiting·—·Phase 3·NCT06803030·189 enrolled

Fed1 trial

A Study to Compare How Tamsulosin is Absorbed to the Body After Administration of Two Types of Tamsulosin Formulation Under Fed and Fasted Conditions in Chinese Healthy Subjects

Completed· Astellas logo

Astellas·Phase 1·NCT02138773·80 enrolled

Dysuria1 trial

Management of Dysuria and Irritative Symptoms After HoLEP: a Prospective Study Evaluating the Efficacy of Alpha-Blocker Therapy

Recruiting·—·N/A·NCT06865430·82 enrolled

Sts1 trial

The Effects of α-adrenergic Receptor Antagonists on Choroid and Pupil

Completed·—·Phase 4·NCT03144596·63 enrolled

Medication1 trial

Investigating Medication vs. Prostatic Urethral Lift: Assessment and Comparison of Therapies for BPH

Unknown status·NNeoTract, Inc.·Phase 4·NCT04987892·250 enrolled

Hypertension1 trial

Treatment of Supine Hypertension in Autonomic Failure

Completed·VVanderbilt University·Phase 1·NCT00223717·152 enrolled

Prostate1 trial

A Clinical Observation Study of a Chinese Patent Medicine Combined With Tamsulosin in Improving Sleep and Nocturia Symptoms After Enucleation of the Prostate

Recruiting·TThe Fourth Affiliated Hospital of Zhejiang University School of Medicine·Phase 4·NCT07357324·136 enrolled

ESS1 trial

A Phase 4 Study With Tamsulosin OCAS to Assess Nighttime Voiding.

Completed· Astellas logo

Astellas·Phase 4·NCT00379067·882 enrolled

Unspecified1 trial

Actual Use Study of Tamsulosin in Men

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT02573311·1,117 enrolled

Sources

References

[1]
ClinicalTrials.gov — 27 trial records for Tamsulosin OCAS. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tamsulosin OCAS compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tamsulosin OCAS. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Astellas company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Astellas

Tamsulosin OCAS

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Benign Prostatic Hyperplasia5 trials

Urinary retention5 trials

Neurogenic bladder2 trials

Lower Urinary Tract Symptom2 trials

Treatment2 trials

Chronic Prostatitis2 trials

Ureteral Stent-Related Symptom1 trial

Fed1 trial

Dysuria1 trial

Sts1 trial

Medication1 trial

Hypertension1 trial

Prostate1 trial

ESS1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News